Nursing care
Iron Dextran and IV Iron: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Iron dextran and other IV iron formulations replace iron stores when oral iron fails or cannot be absorbed. A test dose is given first because dextran carries a real risk of anaphylaxis. The intramuscular form uses Z-track injection to prevent skin staining, and black stools are an expected, harmless effect of iron therapy.
Mechanism, simply
Iron is the building block of haemoglobin, and without enough of it, red blood cells form small and pale and carry less oxygen. Oral iron is the first choice for most patients, but it depends on gut absorption, which is unreliable in malabsorption, inflammatory bowel disease, or after bariatric surgery.
IV iron formulations, including iron dextran, iron sucrose, and ferric carboxymaltose, bypass the gut entirely and deliver iron directly into circulation, where it is taken up by the bone marrow to rebuild haemoglobin stores far faster than oral therapy allows. Iron dextran can also be given intramuscularly, though the IV route is now more common because it avoids the pain and staining of the injection.
Indications you will see on the ward
Iron deficiency anaemia that has not responded to oral iron, or where oral iron is not tolerated because of significant gastrointestinal upset. Patients with chronic kidney disease on dialysis frequently need IV iron because blood loss during dialysis and poor gut absorption make oral replacement inadequate.
It is also used in inflammatory bowel disease during flares, when the gut cannot absorb iron reliably, and in patients who cannot tolerate oral iron's constipation and nausea. Pregnant patients with significant iron deficiency anaemia who need rapid correction before delivery are another common indication, always weighed against the risks of the infusion itself.
Assessment before administration
For iron dextran specifically, a test dose is given before the full dose because of the risk of anaphylaxis. The patient is observed for a set period afterward for signs of a reaction before the remainder of the dose proceeds. This step is specific to dextran and reflects a higher historical rate of severe hypersensitivity reactions compared with newer IV iron formulations.
Have resuscitation equipment and emergency medications accessible for any IV iron infusion, not only the test dose, since delayed reactions can occur. Check baseline iron studies and haemoglobin, confirm no active infection, since iron can feed bacterial growth, and confirm the intramuscular route will use Z-track technique if that route is chosen, to prevent the drug tracking back through tissue and staining the skin.
Toxicity and the antidote
Acute iron toxicity is most often seen with oral overdose, particularly in young children, and progresses through gastrointestinal bleeding, a period of apparent improvement, then metabolic acidosis, liver failure, and shock. IV formulations carry less risk of this pattern but overdose or accumulation is still possible with repeated dosing without monitoring iron stores.
The antidote is deferoxamine, a chelating agent that binds free iron and allows it to be excreted in urine, which characteristically turns a orange-red or vin rosé colour during treatment. Deferoxamine is reserved for confirmed toxicity with elevated serum iron levels and clinical signs, not given prophylactically alongside routine IV iron administration.
Interactions that matter
Oral iron and IV iron are not typically combined, since the goal is either one route or the other depending on tolerance and absorption. Iron reduces the absorption of oral tetracyclines and fluoroquinolones when taken together orally, though this interaction is far less relevant with IV administration.
IV iron should be used cautiously alongside erythropoiesis-stimulating agents such as epoetin alfa, since both increase iron demand and the combination requires closer monitoring of iron studies to avoid either deficiency or overload. Iron should not be given during active infection, since bacteria use iron to grow, and elective IV iron is typically deferred until any infection resolves.
What the patient must be told
Warn the patient that stools will turn black or dark green during iron therapy, whether iron is given orally or IV, and that this is expected and not a sign of bleeding. This single piece of teaching prevents a large share of unnecessary calls and unnecessary stool occult blood testing.
Tell them to report any sudden rash, difficulty breathing, dizziness, or facial swelling during or shortly after an infusion, since these can signal a hypersensitivity reaction. If the intramuscular route was used, explain that some soreness at the site is expected but that visible skin staining should be reported. Advise attending all scheduled infusions, since iron stores are rebuilt over a course of treatment rather than a single dose.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why does iron dextran need a test dose but other IV iron formulations often do not?
Iron dextran has a higher historical rate of anaphylaxis than newer formulations like iron sucrose or ferric carboxymaltose, so a test dose with observation is standard practice before the full dose. Some newer formulations still carry hypersensitivity warnings and require monitoring, but a formal test dose is a dextran-specific step.
Why is Z-track technique used for intramuscular iron dextran?
Z-track displaces the skin and subcutaneous tissue before injection and releases it after, sealing the drug in the muscle layer. Without it, iron dextran can track back along the needle path and permanently stain the skin.
Should a patient be worried about black stools on IV iron?
No, black or dark green stools are an expected effect of iron therapy and do not indicate bleeding on their own. If black stools are accompanied by abdominal pain, dizziness, or a drop in blood pressure, that combination warrants assessment.
Can IV iron be given to a patient with an active infection?
It is generally avoided during active infection because iron can promote bacterial growth and worsen the infection. Elective IV iron administration is typically postponed until the infection has been treated.
More on pharmacology
Guides on this